7,580.07

-140.32

-1.82%

51,770.31

-572.25

-1.09%

25,437.00

-747.73

-2.86%

2,811.84

-47.37

-1.66%

4.9290

-0.0600

-1.20%

19.42

+2.22

+12.91%

3,898.90

-132.50

-3.29%

77,702.52

+583.09

+0.76%

Crude Oil Dec 26

104.12

+2.12

+2.08%

US Private Equity

10,850.63

-82.20

-0.75%

OTC Markets OTCQB - Delayed Quote USD

PharmaTher Holdings Ltd. (PHRRF)

0.0380 -0.0020 (-5.00%)

At close: October 30 at 4:00:00 PM EDT

Loading Chart for PHRRF

Chart Range Bar

Interval:

In partnership with ChartIQ

PharmaTher Builds Portfolio of Personalized, 3D-Printed Peptide Products for New U.S. Peptide Pathway, Led by Colon-Targeted KPV and BPC-157

PharmaTher Builds Portfolio of Personalized, 3D-Printed Peptide Products for New U.S. Peptide Pathway, Led by Colon-Targeted KPV and BPC-157

PharmaTher Submits Orphan Drug and Rare Pediatric Disease Designation Applications to FDA for 3D-Printed Creatine Monohydrate in GAMT Deficiency

PharmaTher Submits Orphan Drug and Rare Pediatric Disease Designation Applications to FDA for 3D-Printed Creatine Monohydrate in GAMT Deficiency

PharmaTher Launches M3DICINES(TM) National Network Program to Provide 3D-Printed Medicines for Rare Diseases, Discontinued Medicines, Drug Shortages and National Emergencies

PharmaTher Launches M3DICINES(TM) National Network Program to Provide 3D-Printed Medicines for Rare Diseases, Discontinued Medicines, Drug Shortages and National Emergencies

PharmaTher Outlines Corporate Strategy and Upcoming Milestones; Launches New Corporate Website and Rebrands PERSONALIZ3D as M3DICINES

PharmaTher Outlines Corporate Strategy and Upcoming Milestones; Launches New Corporate Website and Rebrands PERSONALIZ3D as M3DICINES

PharmaTher Enters into Exclusive North American Distribution Agreement with Craft Health for CraftMake(TM) Pharmaceutical 3D Printing Platform

PharmaTher Enters into Exclusive North American Distribution Agreement with Craft Health for CraftMake(TM) Pharmaceutical 3D Printing Platform

PharmaTher Selects PD Labs, a National 503A Compounding Pharmacy, as the U.S. Center of Excellence for Its Personalized Medicine and Peptide Platform, PERSONALIZ3D(TM)

PharmaTher Selects PD Labs, a National 503A Compounding Pharmacy, as the U.S. Center of Excellence for Its Personalized Medicine and Peptide Platform, PERSONALIZ3D(TM)

PharmaTher Establishes PERSONALIZ3D(TM) to Commercialize a Personalized Medicine Platform Combining Telehealth and Pharmaceutical 3D Printing

PharmaTher Establishes PERSONALIZ3D(TM) to Commercialize a Personalized Medicine Platform Combining Telehealth and Pharmaceutical 3D Printing

PharmaTher Collaborates with Craft Health to Evaluate CraftMake(TM) GMP-Ready Pharmaceutical 3D Printing Platform for Personalized Peptides

PharmaTher Collaborates with Craft Health to Evaluate CraftMake(TM) GMP-Ready Pharmaceutical 3D Printing Platform for Personalized Peptides

PharmaTher Launches Personaliz3D Peptides(TM) to Advance Personalized Peptide Care Following Positive FDA Advisory Committee Recommendations

PharmaTher Launches Personaliz3D Peptides(TM) to Advance Personalized Peptide Care Following Positive FDA Advisory Committee Recommendations

PharmaTher Enters into Collaboration Agreement for KetaMist(R) to Advance Needle-Free Ketamine Treatment Toward FDA Approval

PharmaTher Enters into Collaboration Agreement for KetaMist(R) to Advance Needle-Free Ketamine Treatment Toward FDA Approval

PharmaTher Updates Strategy on Personalized Medicines for Peptides and Psychedelics

PharmaTher Updates Strategy on Personalized Medicines for Peptides and Psychedelics

Mobilize your Website

View Site in Mobile | Classic

Share by: